Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 3, 2003 - Issue 6
Submit an article Journal homepage
18
Views
0
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness of Advair®: fluticasone propionate and salmeterol combination

Benoit Tano Ohio State University Medical Center, 201 Heart and Lung Institute, 473 West 12th Avenue, Columbus, OH 43210, USA. [email protected]
,
Dev Pathak Ohio State University Medical Center, 201 Heart and Lung Institute, 473 West 12th Avenue, Columbus, OH 43210, USA. [email protected]
&
Stephen Hoffmann Ohio State University Medical Center, 201 Heart and Lung Institute, 473 West 12th Avenue, Columbus, OH 43210, USA. [email protected]
Pages 741-747 | Published online: 09 Jan 2014

References

  • Asthma Prevalence, Healthcare Use and Mortality, 2000–2001. National Center for Health Statistics, Centers for Disease Control and Prevention, TX, USA.
  • •Provides US asthma prevalence data and other asthma statistics sources.
  • National Center for Health Statistics. Raw Data from the National Health Interview Survey, US, 1997–1999. Analysis by the American Lung Association Best Practices Division, using SPSS and SUDAAN software.
  • US Centers for Disease Control. Forecasted state — specific estimates of self-reported asthma prevalence — 1998. Morbid. Mortal. 47,1022-1025 (1998).
  • Morbidity & Mortality. 2002 Chart Book on Cardiovascular; Lung and Blood Diseases.' National Heart, Lung and Blood Institute. National Institutes of Health. May 2002.
  • Centers for Disease Control. Surveillance for asthma: United States, 1960–1995. Morbid. Mortal. Wekly Rep. 47(1–55), 1–28 (1998).
  • American Lung Association. Trends in Asthma Morbidity and Mortality Epidemiology and Statistics Unit, Best Practices and Program Services. February 2002.
  • Centers for Disease Control. Surveillance for asthma: United States. 1980–1999. Morbid. Mortal. Wekly Rep. 51(S01), 1–13 (2002).
  • Surveillance for asthma: United States, 1980–1999. MMWR Surveillance Summaries, Centers for Disease Control and Prevention, TX, USA March 29,2002.
  • •Provides asthma prevalence and burden by age, gender and race.
  • Evans R. Asthma among minority children: a growing problem. Chest (1192)101(6), S368—S371 (2002).
  • Martinez FD, Wright AL, Taussig LM et al Asthma and wheezing in the first six years of life. N. Eng. Med. 332,133–138 (1995).
  • Cisternas MG, Blanc PD, Yen IH et al A comprehensive study of the direct and indirect costs of adult asthma. J. Allergy Glitz humunol 111(6), 1212–1218 (2003).
  • ••Provides a good overview of asthma costs.
  • Busse WW, Lemanske RF Jr. Asthma. N Engl. Med 344(5), 350–362 (2001).
  • ••Provides a pathophysiology of asthma and rationale for inhaled corticosteroids and long-acting inhaled bronchodilator use.
  • Markham A, Adkins JC. Inhaled salmeterol/fluticasone propionatecombination. A pharmacoeconomic review of its use in the management of asthma. PharmacoEconomics 18(6), 591–608 (2000).
  • •• First comprehensive pharmacoeconomic review
  • Lyseng-Williamson KA, Plosker GL. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. PharmacoEconomics 21(13), 951–989 (2003). Most recent comprehensive pharmacoeconomic review.
  • Kips JC, Pauwels RA. Long acting inhaled 13(2)-agonist therapy in asthma. Am. Respir. Crit. Care Med 164(6), 923–932 (2001).
  • •Provides a review of long-acting 13-agonist therapy in asthma.
  • Stempel DA, Stanford RII, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin. Ther. 22(12), 1562–1574 (2000).
  • Stempel DA, Mauskopf J, McLaughlin T, Yazdani C, Stanford RII. Comparison ofasthma costs in patients starting fluticasone propionate compared to patients starting Montelukast. Respir Med. 95(3), 227–234 (2000).
  • Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/ fluticasone propionate 50/100mg vs. fluticasone propionate 100mg in adults and adolescents with asthma. Results. PharmacoEconomics 16\(Suppl. 2), 1 5–2 1 (1 9 9 9).
  • Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost-effectiveness of salmeterol/ fluticasone propionate combination product 50/250 1.is twice daily and Budesonide 800Rg twice daily in the treatment of adults and adolescents with asthma. International Study Group. Respir. Med 94(7), 724–732 (2000).
  • Lundback B, Pieters WR, Johansson G eta]. Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma. Introduction and overview. PharmacoEconomics 16\(Suppl. 2), 1–8 (1999).
  • Palmqvist M, Price MJ, Sondi S. Cost- effectiveness analysis of salmeterol/fluticasone propionate 50/250mg vs. fluticasone propionate 250mg in adults and adolescents with asthma. Results. PharmacoEconomics 16\(Suppl. 2), 23–28 (1999).
  • Pieters WR, Lundback B, Sondhi S, Price MJ, Thwaites RMA. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500mg vs. Fluticasone propionate 500mg in adults with asthma. Results. PharmacoEconomics 16\(Suppl. 2), 29–34 (1999).
  • Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. PharmacoEconomics 20 (3), 183–194 (2002).
  • Price MJ, Karia N and Whitehead P Comparison of asthma treatment. Costs of salmeterolifluticasone combination product 50/250mcg b.i.d. with budesonide 800mcg plus Formoterol 12mcg bid. Eur. Respir. 16\(Suppl. 31), S353 (2000).
  • Becker I, Kielborn A, Price MJ etal Cost- effective of salmeterol/fluticasone combination product and budesonide in asthma patients in Germany. Eur. Resp. Soc. 854, 9–10 (1999).
  • Chew FT, Lim TK, Lee BW etal Cost- effectiveness analysis comparing Seretide (salmeterol/fluticasone propionate combination product) and Budesonide for the treatment of asthma in Singapore. Eur Respir. 16\(Suppl. 31), S456 (2000).
  • Lloyd A, Browning D, Shrewsbury S. Cost- effectiveness of salmeterol/fluticasone combination product and budesonide bd in the United Kingdom (asthma). Am. Respir. Grit. Care Med. 161\(Suppl. 3 Pt 2), A196 (2000).
  • Parnaby A, Lloyd A, Browning D etal A comparison of the cost-effectiveness of salmeterol/fluticasone combination inhaler and budesonide in the management of asthma. Thomx55\(Suppl. 3), A64 (2000).
  • Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P Cost-effectiveness comparison of salmeterol/fluticasone propionate versus Montelukast in the treatment of adults with persistent asthma. PharmacoEconomics 20(13), 909–918 (2002).
  • Calhoun W, Nelson H, Nathan R et al Comparison of fluticasone propionate-salmeterol combination therapy and Montelukast in patients who are symptomatic on short acting 132-agonists alone. AIR I Respir Grit. Care Merl 164, 759–763 (2001).
  • Leibman C, Pathak D, Bowers B eta]. Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma. I Allergy Gun. Immunol 109(Suppl.) S185 (2002).
  • Stanford RII, Borker R, Dorinsky P eta]. The costs and efficacy of fluticasone propionate/salmeterol combination versus Montelukast in the treatment of adults with persistent asthma. Chest 122(Suppl.), 183–184 (2002).
  • Ringdal N, Efiraz A, Pruzinec R etal The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir. Med 97(3), 234–241 (2003).
  • Jenkins C, Wilson J, Rutherford C eta]. Asthma management costs are lower with combination fluticasone/salmeterol (250/ 50 mcg bd) in a single inhaler than with budesonide 800 mcg bd plus eformoterol 12mcg bd via separate inhalers. Respimlogy 7(Suppl.) A20 (2002).
  • Price MJ, Briggs AH. The cost-effectiveness of achieving asthma control with the combination product salmeterol/fluticasone propionate or formoterol/budesonide. Eur. Respir. 18\(Suppl. 33), 159 (2001).
  • Rance L, Musin A. Asthma management costs in Canada are lower with combination fluticasone propionate/salmeterol (250/50 mcg b.i.d.) in a single inhaler than with budesonide 800mcg b.i.d. plus eformoterol 12mcg b.i.d. via separate inhalers. Chest 122(Suppl.), S2—S3 (2002).

Websites

  • American Lung Association. January, Trends Morbid. Mortal (2001). www.lungusa.org/data/asthma/ ASTHMA1 .pdf(Accessed November 2003)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.